BAXTER INTL INC's ticker is BAX and the CUSIP is 071813109. A total of 885 filers reported holding BAXTER INTL INC in Q3 2023. The put-call ratio across all filers is 0.40 and the average weighting 0.2%.
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Governors Lane LP | 267,500 | $10,095,450 | 1.61% |
| CINCINNATI FINANCIAL CORP | 1,617,648 | $61,050,036 | 1.47% |
| Olstein Capital Management, L.P. | 222,000 | $8,378 | 1.44% |
| TSFG, LLC | 103,975 | $3,924 | 1.40% |
| Coho Partners, Ltd. | 1,694,087 | $63,934,835 | 1.36% |
| GENERATION INVESTMENT MANAGEMENT LLP | 6,563,608 | $247,710,566 | 1.30% |
| PointState Capital LP | 2,000,000 | $75,480,000 | 1.29% |
| COOKE & BIELER LP | 3,343,850 | $126,196,899 | 1.23% |
| Canal Insurance CO | 100,000 | $3,774 | 1.08% |
| Camelot Portfolios, LLC | 29,070 | $1,097,127 | 1.05% |
| TOBAM | 340,510 | $12,851 | 1.03% |
| WASHINGTON CAPITAL MANAGEMENT, INC | 29,165 | $1,100,687 | 1.01% |
| Cascade Investment Advisors, Inc. | 33,595 | $1,267,875 | 1.00% |
| M. Kulyk & Associates, LLC | 92,551 | $3,492,857 | 0.97% |
| Point72 Europe (London) LLP | 403,100 | $15,212,994 | 0.93% |
| PZENA INVESTMENT MANAGEMENT LLC | 5,721,656 | $215,935,297 | 0.93% |
| Rodgers Brothers Inc. | 140,423 | $5,299,572 | 0.90% |
| WHITEBOX ADVISORS LLC | 728,500 | $27,493,590 | 0.87% |
| Invenomic Capital Management LP | 534,536 | $20,173,389 | 0.85% |
| BEACON INVESTMENT ADVISORS LLC | 31,110 | $1,174,079 | 0.83% |
About BAXTER INTL INC
Baxter International Inc. is a global healthcare company that specializes in developing and manufacturing medical products and therapies. The company has a long history of innovation and has been at the forefront of developing life-saving treatments for patients around the world.
Baxter's product portfolio includes a wide range of medical devices, pharmaceuticals, and biotechnology products. The company's products are used in hospitals, clinics, and other healthcare settings to treat a variety of conditions, including hemophilia, immune disorders, kidney disease, and other chronic and acute medical conditions.
Baxter's commitment to innovation has helped the company maintain a strong position in the healthcare industry. The company invests heavily in research and development, and has a strong pipeline of new products in development.
Baxter's leadership team is also a key strength of the company. The CEO, José Almeida, has a strong track record of success in the healthcare industry, and has been instrumental in driving the company's growth and success.
Overall, Baxter International Inc. is a strong and innovative company that is well-positioned to continue delivering value to patients, healthcare providers, and investors alike. With a strong product portfolio, a commitment to innovation, and a talented leadership team, Baxter is a company that investors should keep an eye on in the years to come.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
External links
This page lists BAXTER INTL INC's shareholders in Q3 2023. To view BAXTER INTL INC's shareholder history, click here.